Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EMB-01

Phase 2Small molecule

SShanghai EpimAb Biotherapeutics Co., Ltd.

EMB-01 is one of 127 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

4

Indications

5

Total Trials

2

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Intestinal CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Smoking CessationActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Smoking CessationPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Sutent

Lynparza

Xeloda

XL092

PF-08634404

FOLFOX-4

Mfolfoxiri

DDominik Paul Modest

Oxaliplatin, /m2

Eylea

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT07314294

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Unknown status·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT03797391·186 enrolled

Metastatic Colorectal Cancer1 trial

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Recruiting·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 2·NCT07314294·54 enrolled

Lung Cancer1 trial

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Unknown status·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT05498389·115 enrolled

Smoking Cessation1 trial

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Unknown status·RRose Research Center, LLC·Phase 2/3·NCT04868253·25 enrolled

Intestinal Cancer1 trial

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT05176665·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for EMB-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EMB-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EMB-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai EpimAb Biotherapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai EpimAb Biotherapeutics Co., Ltd.

Related News